Product Information
DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Ascend Laboratories, LLC, priced at $0.8569 per EA under NDC 67877047560. Its NADAC has been published 184 times since Dec 21, 2022.
Strength
150 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877047560
Classification
Generic
Dosage Form
CAPSULE, COATED PELLETS
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208040On Market Since
6/20/2022
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 184 times since Dec 21, 2022, and over the history we have for it it has declined 87.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8569 per EA |
|---|---|
| All-time high | $6.9462 (Jul 12, 2023) |
| All-time low | $0.8446 (Feb 18, 2026) |
| 52-week high | $1.4231 |
| 52-week low | $0.8446 |
| Median price | $1.9348 |
| Average price | $2.8358 |
| Largest weekly change | -54.3% (Sep 20, 2023) |
| Weeks tracked | 184 |
| Tracking since | Dec 21, 2022 |
Generic Alternatives
The matcher finds 4 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 4 manufacturers (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Ascend Laboratories, LLC, is $0.8569 per EA (NDC 67877047560), effective Jun 24, 2026.
How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 87.2%. It has been tracked across 184 weekly CMS publications since Dec 21, 2022.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?
Since Dec 21, 2022, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.8446 (Feb 18, 2026) to a high of $6.9462 (Jul 12, 2023), with a median of $1.9348 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?
4 NADAC-published products share the same active ingredient, strength, and dosage form as DABIGATRAN ETEXILATE 150 MG CP, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 150 MG CP?
DABIGATRAN ETEXILATE 150 MG CP (NDC 67877047560) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification